Regeneron begins first clinical trials of antibody cocktail for treatment, prevention of COVID-19
The antibody cocktail approach may work better for elderly and immuno-compromised patients
Regeneron Pharmaceuticals announced on Thursday the start of the first clinical trial of its investigational dual antibody cocktail for the prevention and treatment of COVID-19.
It is called REGN-COV2.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
The program will cover four study areas: hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, uninfected people in groups that are at high-risk of exposure and uninfected people with close exposure to a COVID-19 patient.
WIDESPREAD MASK-WEARING COULD PREVENT CORONAVIRUS SECOND WAVES: STUDY
“We have created a unique anti-viral antibody cocktail with the potential both to prevent and treat infection, and also to preempt viral ‘escape,’ a critical precaution in the midst of an ongoing global pandemic,” said George D. Yancopoulos, co-founder and chief scientific officer of Regeneron. “REGN-COV2 could have a major impact on public health by slowing spread of the virus and providing a needed treatment for those already sick – and could be available much sooner than a vaccine."
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| REGN | REGENERON PHARMACEUTICALS INC. | 762.34 | +12.12 | +1.62% |
The antibody cocktail approach may work better for elderly and immuno-compromised patients, who don't always respond well to vaccines, Yancopoulos added.
Regeneron scientists evaluated fully-human antibodies produced by the company’s mice, which have been genetically-modified to have a human immune system, in addition to antibodies isolated from people who have recovered from COVID-19.
CLICK HERE TO READ MORE ON FOX BUSINESS
The company used the same cocktail approach to develop a triple antibody treatment for Ebola that is currently under regulatory review by the Food and Drug Administration.